Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619236 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
A Phase 3 study of Platinum-resistant Ovarian Cancer, sponsored by Genmab.
- Active
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT06619236: Active Phase 3 study of Platinum-resistant Ovarian Cancer, sponsored by Genmab.
NCT06619236 is a Phase 3 study of Platinum-resistant Ovarian Cancer that is active but no longer recruiting, run by Genmab. The registered enrollment target is 530 participants, above the 155-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (242% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619236, a Phase 3 study of Platinum-resistant Ovarian Cancer, is active but no longer recruiting, sponsored by Genmab.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Primary Outcome
PFS is defined as the time from the date of randomization to the date of the first documented progression or death (PD) due to any cause, whichever occurs first based on response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Topotecan
- DRUG Rina-S
- DRUG Pegylated liposomal doxorubicin (PLD)
Study Locations (20)
Florida
- SCRI - Florida Cancer Specialists - South Region Research Office - Fort Myers
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Orlando Health Cancer Institute - Downtown Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
- SCRI - Florida Cancer Specialists - West Palm Beach - West Palm Beach
California
- Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center - Burbank
- University of California San Diego Moores Cancer Center - La Jolla
- USCF Mission Bay - San Francisco
- Kaiser Permanente - Vallejo Medical Center - Vallejo
Connecticut
- Hartford Hospital - Hartford
- Yale School of Medicine - New Haven
- Norwalk Hospital - Norwalk
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Northside Hospital Atlanta - Atlanta
- Augusta University Georgia Cancer Center - Augusta
Arizona
- Arizona Center for Cancer Care (ACCC) - Biltmore - Scottsdale
- University of Arizona Cancer Center - Research and Administration at Main Campus - Tucson
Alaska
- Alaska Women's Cancer Care - Anchorage
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center - Aurora
Hawaii
- Kapi'olani Medical Center for Women and Children - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2028-05-23 |
| Phase | Phase 3 |
What the registry record for NCT06619236 still lists
NCT06619236 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (242% higher).
The record links to 1 condition, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.
NCT06619236 names 20 study sites across 8 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06619236 about?
NCT06619236 is a clinical study titled "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer". This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment...
What is the current status of trial NCT06619236?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2025-02-07. Estimated completion is 2028-05-23.
What conditions does trial NCT06619236 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT06619236?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Topotecan (DRUG), Rina-S (DRUG), Pegylated liposomal doxorubicin (PLD) (DRUG).
Who is sponsoring clinical trial NCT06619236?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619236 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06619236's enrollment target sits among peer trials
530 1st of 17 higher than 17 of 17 other Platinum-resistant Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Platinum-resistant Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RECRUITING · Phase 3
-
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
RECRUITING · Phase 2
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI